BMY vs GCMG · P/E 17, rev $24.46B vs P/E 21, rev $259.1M
Bristol-Myers Squibb Company (BMY) versus GCM Grosvenor Inc (GCMG) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
GCM Grosvenor Inc (GCMG) is a asset management company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported GCMG revenue for 2026-06-30 was $259.1M. Net income was $15.0M. GCMG currently screens at market cap $641.9M and trailing P/E 21.3.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. GCMG currently screens at market cap $641.9M and trailing P/E 21.3.
Not investment advice. Open the BMY and GCMG stock pages for the full models.
Not investment advice.